Actualités sur Krankheit
- plus
Grünenthal and Averitas Pharma announce completion of recruitment for Phase III clinical trial with QUTENZA® in post-surgical neuropathic pain
Aachen, Germany/Morristown, N.J. (ots) - - The Phase III trial AV001 aims to evaluate QUTENZA® in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical procedures[1], thus affecting more than 3 million people with surgical procedures ...
plusFirst participants enrolled in first-in-human Phase I clinical trial with nociceptin (NOP) receptor agonist
Aachen, Germany (ots) - Today, Grünenthal announced that the first participants have been enrolled in a first-in-human Phase I clinical trial for a nociceptin (NOP) receptor agonist. The trial will include 90 healthy volunteers and aims to demonstrate a favourable safety and tolerability profile and to confirm the ...
plusSchweizerischer Nationalfonds / Fonds national suisse
Full-time employees face higher risk of cancer
Bern (ots) - Working at 100% is linked to a higher incidence of the disease, according to an SNSF-funded study. Self-employed men and women who stay at home fared best, but the explanation is not as straightforward as it might seem. Some of the risk factors for cancer are well known - smoking, alcohol, a sedentary lifestyle - while others are a bit harder to explain. For example, work. As part of the completed, ...
plusNew insights highlight unmet needs for people living with Lennox-Gastaut syndrome and significant burden of the disease
Brussels (ots/PRNewswire) - - New data presented at the 15th European Epilepsy Congress highlight lengthy delays in Lennox-Gastaut syndrome (LGS) diagnosis in Europe and significant disease burden from both seizure and non-seizure impairments[1] - LGS is a severe childhood-onset developmental and epileptic ...
plusINSIGHTEC; Charles River Laboratories International, Inc.
Charles River and Insightec Announce Strategic Collaboration to Advance Therapeutic Development Utilizing Focused Ultrasound in Neuroscience
Wilmington, Mass., Miami and Haifa, Israel (ots/PRNewswire) - Collaboration stands to advance novel therapeutic applications across multiple neurologic conditions Charles River Laboratories International, Inc. (NYSE: CRL) and Insightec, a global healthcare company dedicated to using focused ultrasound to transform ...
plus- 2
Press Release Kunstmuseum St.Gallen | RM: Anus Horribilis
Un documentplus Schweizerischer Nationalfonds / Fonds national suisse
Back pain sufferers need patience more than anything else
Bern (ots) - Temporary complaint or chronic affliction: a research team funded by the SNSF has identified typical trajectories for back pain. Psychosocial factors play a smaller role than expected. Back pain is a widespread condition: at least once in their lives, almost 85% of people will experience pain in the area of the lumbar spine, in other words between the bottom rib and the tailbone. Treating this correctly is ...
plusSoterios Pharma Announces Positive Topline Results from Phase II Study of STS-01 in the Treatment of Mild / Moderate Alopecia Areata
London (ots/PRNewswire) - - Once-daily topical treatment of mild / moderate alopecia areata (AA) with 1% STS-01 met the primary efficacy endpoint of >30% Severity of Alopecia Tool (SALT) score improvement compared to patients receiving placebo ...
plusSchweizerischer Nationalfonds / Fonds national suisse
Breath analysis to monitor health status in intensive care
plusMedison Pharma; Alnylam Pharmaceuticals
Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia
Zug, Switzerland (ots/PRNewswire) - - The expanded partnership will allow Alnylam and Medison to help accelerate access for patients in multiple regions under one global alliance - Medison, the creator and leader of the multi-regional partnership category, will utilize its unique, unified platform for efficient ...
plusHuma and Merck KGaA, Darmstadt, Germany Launch Innovative App to Support Bladder Cancer Patients
London (ots/PRNewswire) - Huma Therapeutics ("Huma"), a leader in global digital health innovation, together with Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the launch of their innovative bladder cancer treatment companion app in the United Kingdom. This collaboration underscores Merck KGaA, Darmstadt, Germany and Huma's ...
plus- 2
Swiss Malaria Group celebrates World Malaria Day and launches a video quiz campaign
plus Norgine B.V. submits Marketing Authorisation Application via Project Orbis for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma
Amsterdam (ots/PRNewswire) - Norgine B.V. today announced its first marketing authorisation application submissions on 10 April 2024, seeking approval for eflornithine in high-risk neuroblastoma (HRNB), via Project Orbis in Australia, Switzerland and the United Kingdom. This milestone supports Norgine's efforts to ...
plusEuropean Parliament Recognizes Essential Tremor as Official Disease in Ground-Breaking Declaration
Brussels (ots/PRNewswire) - The Insightec-organized conference resulted in a Joint Declaration, promising new hope for patients suffering from the condition The European Parliament, in collaboration with Insightec and patient advocacy groups, has taken a historic step forward in the healthcare realm by signing a ...
plus- 11
FDI World Dental Federation releases powerful video message unifying voices in celebration of World Oral Health Day
plus Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand
Research Triangle Park, N.C. and Uxbridge, England (ots/PRNewswire) - Agreement pairs Norgine's commercial expertise and leading European footprint with PEDMARQSI™, the first and only approved therapy in the European Union and U.K. for reducing the risk of cisplatin-induced hearing loss in pediatric patients with ...
plus- 4
FDX Fluid Dynamix and Fraunhofer IPK to Collaborate with Lonza on Novel Nanoparticle Formulation Technology Platform FDmiX
plus Epitomee® announces the filing of a novel Weight Loss Capsule for FDA clearance
Caesarea, Israel (ots/PRNewswire) - Epitomee® (TASE: EPIT) announced today that on February 27, 2024, it has submitted its Weight Loss Capsule for FDA clearance in the USA, reaching a significant milestone in the company's journey. The Epitomee® capsule offers an innovative, orally administered, drug free, and clinically proven as effective and safe solution, for ...
plusPhagenesis, a medical device company specializing in the treatment of swallowing disorders, successfully closes a $42M Series D financing round led by EQT Life Sciences and Sectoral Asset Management
Manchester, England (ots/PRNewswire) - Phagenesis, a pioneering UK company which has developed a revolutionary neurostimulation system to treat swallowing dysfunction, has closed a $42M Series D financing all equity investment round. The combined European and United States investment syndicate was led by EQT Life ...
plusProcare Health: Silencing HPV infection may exacerbate the physiological effects of the emotional burden
Valencia, Spain (ots/PRNewswire) - The emotional impact of a human papillomavirus (HPV) diagnosis is significant, often leading to feelings of fear, worry, guilt, and self-stigmatization among women. Recognizing the importance of addressing these emotions alongside physical symptoms, Procare Health organized the ...
plusInsightec's Groundbreaking Transcranial MR-Guided Focused Ultrasound (MRgFUS) Approved for Additional Reimbursement for Essential Tremor in Germany
Berlin (ots/PRNewswire) - Germany is latest – and largest – European country to enable substantial access to focused ultrasound, offering new hope of relief for those suffering with movement disorders Insightec, a pioneer and global leader in focused ultrasound, is pleased to announce that its transcranial ...
plusJohnson & Johnson Biosense Webster
Biosense Webster Announces CE Mark approval in Europe for VARIPULSE™ Pulsed Field Ablation (PFA) Platform
Irvine, Calif. (ots/PRNewswire) - - Regulatory approval for the first fully integrated PFA system with a CARTO-enabled simple and reproducible workflow. - Integrated with the world's leading CARTO™ 3D Cardiac Mapping System for the treatment of symptomatic drug refractory recurrent paroxysmal atrial fibrillation ...
plusSchweizerischer Nationalfonds / Fonds national suisse
Wie Fadenwürmer altern - und was das für die Menschen bedeuten könnte
Bern (ots) - Ein Protein reduziert die Lebenserwartung von Fadenwürmern. Diese Entdeckung wirft die Frage auf, ob es beim Menschen ebenfalls den Alterungsprozess mitbewirkt. Selbst von den am besten erforschten Genen und Proteinen kennt man noch längst nicht alle Geheimnisse. Wie das Schweizer Taschenmesser haben sie zahlreiche, teilweise unbekannte Funktionen. Mit ...
plusHearing loss company Acousia announces first patient enrolled in its Phase 2 PROHEAR-Study
Tübingen, Germany (ots) - Acousia Therapeutics GmbH, a Tübingen-based clinical stage biotech company focused on the enhancement and preservation of natural hearing, just announced the randomization of the first patient for the PROHEAR-Study. The PROHEAR-Study is a placebo-controlled, Phase 2a study with split-body design, which investigates the otoprotective efficacy ...
plusINSIGHTEC MR-GUIDED FOCUSED ULTRASOUND TECHNOLOGY RECOMMENDED FOR NATIONAL COVERAGE FOR DUTCH PATIENTS LIVING WITH ESSENTIAL TREMOR
Amsterdam (ots/PRNewswire) - The Netherlands is the latest European country to recommend national coverage for the treatment of essential tremor with focused ultrasound. Insightec, a pioneer and global leader in focused ultrasound, has welcomed a positive recommendation report[1] from the Dutch Healthcare Institute ...
plusEpitomee® Announces Successful Completion of Pivotal Clinical Trial for Innovative Weight Loss Capsule
Caesarea, Israel (ots/PRNewswire) - Epitomee® announces the successful completion of the RESET pivotal clinical trial, for its weight loss capsule. The randomized placebo controlled, double blind trial, investigated the safety and efficacy of Epitomee® capsule versus the sham capsule control, alongside lifestyle ...
plusAcousia Therapeutics attracts new investor on its path to make hearing loss a treatable disease
Tübingen (ots) - - German pioneer biotech accelerates hearing loss solution development with fresh capital boost Acousia Therapeutics GmbH, a clinical-stage biotech company developing drug candidates against acute and chronic forms of hearing loss, proudly announces Esperante Ventures as the latest addition to its esteemed group of investors. The infusion of fresh ...
plusMedison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo® (cemiplimab) in Multiple Countries
Zug, Switzerland (ots/PRNewswire) - - Libtayo (cemiplimab) is a leading PD-1 inhibitor that has shown efficacy in the treatment of certain patients with cutaneous squamous cell carcinoma, advanced basal cell carcinoma, advanced non-small cell lung cancer and advanced cervical cancer, and is approved by regulatory ...
plusSchweizerischer Nationalfonds / Fonds national suisse
How robots make people hear voices
Bern (ots) - Researchers have developed a method for triggering auditory hallucinations in healthy people. They are investigating the causes of a phenomenon that can be a huge burden for people with psychiatric illnesses. Studies indicate that five to ten per cent of all people sometimes hear voices - those of dead relatives or higher beings, for example - without having any kind of illness. In other words, the phenomenon is not restricted to people with psychiatric ...
plus